Insider Transactions in Q2 2021 at Nektar Therapeutics (NKTR)
Insider Transaction List (Q2 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 17
2021
|
Gil M Labrucherie SVP, COO & CFO |
SELL
Open market or private sale
|
Direct |
7,898
-3.05%
|
$142,164
$18.3 P/Share
|
|
May 17
2021
|
John Northcott SVP & Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
6,085
-2.85%
|
$109,530
$18.3 P/Share
|
|
May 17
2021
|
Howard W Robin President & CEO |
SELL
Open market or private sale
|
Direct |
11,560
-2.59%
|
$208,080
$18.3 P/Share
|
|
May 17
2021
|
Jillian B. Thomsen Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
13,391
-8.14%
|
$241,038
$18.3 P/Share
|
|
May 17
2021
|
Mark Andrew Wilson Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
1,917
-2.5%
|
$34,506
$18.3 P/Share
|
|
May 17
2021
|
Jonathan Zalevsky Chief R&D Officer |
SELL
Open market or private sale
|
Direct |
31,111
-11.69%
|
$559,998
$18.3 P/Share
|
|
May 12
2021
|
Robert Chess |
SELL
Open market or private sale
|
Direct |
8,000
-2.77%
|
$152,000
$19.34 P/Share
|
|
May 12
2021
|
Robert Chess |
BUY
Exercise of conversion of derivative security
|
Direct |
8,000
+2.7%
|
$104,000
$13.8 P/Share
|
|
Apr 14
2021
|
Robert Chess |
SELL
Open market or private sale
|
Direct |
8,000
-2.77%
|
$144,000
$18.98 P/Share
|
|
Apr 14
2021
|
Robert Chess |
BUY
Exercise of conversion of derivative security
|
Direct |
8,000
+2.7%
|
$104,000
$13.8 P/Share
|